Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Children’s eating habits are strongly influenced by their parents' weight status, with those having overweight or obese ...

Obesity affects both physical and mental health, leading to body-image issues and emotional eating. Dr. Nand Kumar of AIIMS ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Ultraprocessed food consumption in preschoolers is associated with increased body fat, particularly in boys, underscoring the ...

Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs ...

Although obese individuals are at greater risk of diabetes, high blood pressure or high cholesterol, not all obese people ...

The economic burden of obesity is also significant. In the Finger Lakes, excess medical spending due to obesity is estimated ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...